GlycoMimetics Retained Earnings (Accumulated Deficit) 2012-2024 | GLYC

GlycoMimetics retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

GlycoMimetics Retained Earnings (Accumulated Deficit) 2012-2024 | GLYC

GlycoMimetics retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.7B
Takeda Pharmaceutical (TAK)$47.3B
Merck (MKGAF)$23.7B
Astellas Pharma (ALPMY)$21.5B
Summit Therapeutics (SMMT)$19B
Sandoz Group AG (SDZNY)$17.5B
United Therapeutics (UTHR)$15.4B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$12.4B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6.1B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Crinetics Pharmaceuticals (CRNX)$4.2B
Corcept Therapeutics (CORT)$4.1B
Dyne Therapeutics (DYN)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
PTC Therapeutics (PTCT)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.5B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.5B
Cassava Sciences (SAVA)$1.5B